Iran Launches 63 New Domestic Medicines, Saving Up to $30 Million in Foreign Currency

TEHRAN (ANA)- Iran has introduced 63 new locally produced pharmaceutical products, including 19 first-of-their-kind formulations, a development expected to save the country $25–30 million annually by reducing dependence on imported medicines and raw materials.

News ID : 10602

The announcement was made in Tehran on Sunday by Mohammad Naderi Alizadeh, CEO of Iran’s Tamin Pharmaceutical Investment Holding (TIPICO), which oversees the full pharmaceutical value chain—from research and development to manufacturing, distribution, and marketing.

TIPICO operates 24 subsidiaries and three affiliated companies nationwide, producing 549 pharmaceutical data-x-items that cover most therapeutic needs in Iran. The company controls 25–30% of the domestic drug distribution market and supplies medicines to over 40% of medical universities, including many serving low-income populations, despite large outstanding receivables in the health sector.

Alizadeh highlighted that TIPICO has streamlined its operations by closing all loss-making subsidiaries, boosting financial performance. Profits from finished-product units rose 138% in the first ten months of the year (March 21, 2025–January 20, 2026), while total group profits more than doubled.

Among the newly unveiled products, 10 are active pharmaceutical ingredients (APIs), 46 are finished medicines and supplements, and seven are veterinary drugs, collectively projected to save $25–30 million annually in foreign currency. Strategic products, including type-2 diabetes and weight-loss medicines, as well as insulin glargine, are expected to enter the market next year pending regulatory approval.